The global animal vaccine market size was valued at USD 12 billion in 2025 and is projected to grow from USD 12.72 billion in 2026 to USD 20.27 billion by 2034, registering a CAGR of 6% during the forecast period from 2026 to 2034. North America dominated the animal vaccine market with a market share of 38.5% in 2025.
Animal vaccines are biological products used to protect livestock, poultry, and companion animals from infectious diseases by strengthening their immune systems. They help reduce disease outbreaks, improve animal health, and support safe food production.
Download a Free Sample To learn more about this report,
Adoption of mRNA Vaccines for Animal Diseases
Animal vaccine market analysis shows that mRNA technology is shifting veterinary vaccine development toward flexible platforms that can be designed and adjusted for specific pathogens. The rapid production potential of mRNA platforms supports faster development of candidate vaccines when new animal diseases or viral variants emerge. Moderna and Merck Animal Health have explored mRNA-based veterinary vaccines, including research focused on respiratory diseases in livestock.
Integration of DIVA Vaccines for Disease Surveillance
DIVA vaccines are transitioning animal disease control from vaccination alone toward systems that also support differentiation between infected and vaccinated animals. DIVA-compatible vaccines and diagnostic tests allow surveillance programs to identify naturally infected animals without confusing them with vaccinated populations, strengthening outbreak monitoring and control. The approach has been particularly relevant to livestock diseases such as foot-and-mouth disease, where separating infection status from vaccination status supports more effective disease-management programs.
Demand for Companion Animal Preventive Healthcare and Advances in Recombinant and Subunit Vaccine Technologies Drive Market
Greater focus on preventive healthcare for dogs and cats creates demand for routine vaccines that protect against common infectious diseases. Veterinary clinics increasingly include core vaccinations as part of regular wellness programs, supporting recurring demand for companion animal vaccines. Rabies, canine parvovirus, feline panleukopenia, and other infectious diseases represent key applications for preventive vaccination. Higher participation in routine veterinary care supports wider vaccine use among companion animals. This shift toward preventive care therefore drives demand in the Animal Vaccine Market.
Advances in recombinant and subunit technologies expand the supply of veterinary vaccines designed around specific pathogen antigens. These platforms can support targeted immune responses while providing manufacturers with alternative approaches to conventional whole-pathogen vaccines. Recombinant vaccines for diseases such as bovine respiratory disease and poultry infections demonstrate practical applications of these technologies. Broader availability of antigen-specific formulations gives veterinary vaccine manufacturers more options for developing disease-specific products. These technological advances therefore strengthen vaccine supply and support market growth.
Limited Cold Chain Infrastructure and Shortage of Rural Veterinary Professionals Restrain Market Expansion
Limited cold chain and vaccine storage infrastructure can affect the quality and stability of animal vaccines during transportation and storage. Inadequate refrigeration, unreliable power supply, and poor temperature monitoring can increase the risk of vaccine spoilage and reduce availability in remote areas. As a result, distribution challenges can slow vaccination adoption and restrict Animal Vaccine Market growth.
Shortage of veterinary professionals in rural areas limits access to vaccination services and reduces the capacity to conduct regular animal immunization programs. Limited availability of trained personnel can make vaccine administration, disease monitoring, and follow-up care more difficult for livestock owners. Consequently, gaps in veterinary services can slow vaccine adoption and restrain market expansion.
Expansion of Animal Vaccines in Aquaculture and Development of Thermostable Animal Vaccine Formulations Offers Growth Opportunities
Aquaculture producers, fish-health companies, veterinary vaccine manufacturers, and aquatic animal clinics can use vaccines to manage infectious diseases in farmed fish and shrimp. Revenue avenues include species-specific vaccines, vaccination services, and specialized products for commercial aquaculture operations. Companies such as MSD Animal Health and Zoetis have veterinary vaccine portfolios that include aquatic animal health applications.
Vaccine manufacturers, veterinary distributors, livestock producers, and rural animal-health providers can benefit from formulations that remain stable under less stringent temperature-control conditions. Revenue opportunities include thermostable vaccines, improved distribution formats, and products suited to regions with limited cold-chain infrastructure. Companies such as Ceva Santé Animale and Boehringer Ingelheim Animal Health operate across veterinary vaccine markets where improved vaccine stability can support broader product reach.
Vaccine Efficacy Variability and Complex Regulatory Requirements Across Animal Species and Countries
Differences in animal species, immune responses, and circulating disease strains can affect vaccine performance across markets. Companies need to adapt formulations and validate efficacy for different livestock and companion animals, increasing development complexity and limiting broad product deployment.
Different approval, safety, labeling, and quality requirements across countries increase the time and cost required to commercialize animal vaccines. Companies operating across multiple regions must maintain separate regulatory strategies, which can slow product launches and market expansion.
The attenuated vaccines segment accounted for a share of 27.8% in 2025 due to their strong immune response, established use in veterinary healthcare, and effectiveness against a wide range of animal diseases. Their broad application across livestock, poultry, and companion animals further supports their dominant market position.
The DNA Vaccines segment is expected to grow at a CAGR of 9.1%, driven by their ability to provide targeted immune responses, stable formulations, and potential for rapid development against emerging animal diseases. The inactivated vaccines segment supports market growth through safe and stable vaccine formulations that help protect animals against infectious diseases. The subunit vaccines segment contributes through targeted antigens that provide effective immune protection with improved safety profiles. The toxoid vaccines segment supports adoption through vaccines designed to protect animals against toxin-producing bacterial diseases. The conjugate vaccines segment contributes through enhanced immune responses against specific bacterial infections. The recombinant vaccines segment supports market growth through targeted antigen production and advanced vaccine development technologies.
Request Customizationto receive a tailored report.
The companion animal segment accounted for a share of 34.7% in 2025 due to the widespread adoption of preventive vaccination for dogs, cats, and other household pets. Regular veterinary care and increased focus on companion animal health further support its dominant market position.
The aquaculture segment is expected to grow at a CAGR of 8.5%, driven by the increasing use of vaccines to prevent infectious diseases, improve fish health, and reduce losses in aquaculture production. The livestock animal segment supports market growth through vaccination programs that prevent infectious diseases and improve the health and productivity of cattle, pigs, and other farm animals.
Speak to an Analystto discuss market opportunities.
The North America animal vaccine market accounted for a regional share of 38.5% in 2025. This position is supported by strong veterinary healthcare infrastructure, widespread adoption of preventive animal healthcare, and established livestock and companion animal sectors across the region.
The U.S. animal vaccine market could benefit from expanding livestock production, as the USDA projects the U.S. cattle inventory to reach 91.6 million head by 2034, while broiler chicken production is projected to increase from 47.9 billion pounds in 2026 to 53.4 billion pounds in 2034, supporting continued demand for animal health and vaccination products. The Canada animal vaccine market could benefit from a larger livestock base, as Statistics Canada reported 12.1 million cattle and calves on July 1, 2026, up 3.2% year over year, while the number of calves increased 4.6% to 3.9 million, indicating a strengthening cattle population that can support future demand for preventive animal healthcare.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific animal vaccine market is expected to grow at a CAGR of 8.9% during the forecast period, showcasing the fastest-growing regional market. This growth is supported by expanding livestock production, increasing focus on animal health, and greater adoption of preventive veterinary care across the region. The Japan animal vaccine market could benefit from continued livestock production, as Japan’s Ministry of Agriculture, Forestry and Fisheries targets 2030 production of 1.7 million tonnes of chicken meat and 780 million tonnes of milk, supporting sustained requirements for animal health and disease-prevention products.
The China animal vaccine market could benefit from continued livestock production and stronger disease prevention, as China’s State Council targets 75% or more of livestock and poultry breeding to be conducted at large scale by 2030, alongside an 85% comprehensive livestock-waste utilization rate, supporting more structured animal-health management. The South Korea animal vaccine market could benefit from continued livestock production, as South Korea’s Ministry of Agriculture, Food and Rural Affairs projects that by 2030 livestock numbers in a representative local assessment could include 13.6% growth in Korean cattle, 1.5% in pigs, and 7% in chickens, increasing the need for preventive animal healthcare. The India animal vaccine market could benefit from expanding animal-source food production, as NITI Aayog projects India’s milk production to reach 308–329 million tonnes by 2030–31 under high-income-growth scenarios, while meat production is projected at 12–13 million tonnes, supporting continued demand for livestock health and vaccination products.
The Europe animal vaccine market accounted for a regional share of 28.4% in 2025. This position is supported by established veterinary healthcare infrastructure, strong livestock production, and widespread adoption of preventive animal health practices across the region. The U.K. animal vaccine market could benefit from continued livestock production, as the UK government projects that the number of dairy cows will remain around 1.6 million through 2030, while beef cattle numbers are expected to remain close to 1.0 million, supporting sustained demand for livestock health and disease-prevention products.
The Germany animal vaccine market could benefit from continued livestock production, as the European Commission projects EU milk production to reach 162 million tonnes by 2035, while Germany remains one of the bloc’s major milk-producing countries, supporting ongoing requirements for livestock health and vaccination products. The France animal vaccine market could benefit from sustained livestock activity, as the European Commission projects EU beef production to remain around 6.3 million tonnes by 2035, with France continuing to account for a significant share of EU cattle production, supporting demand for preventive animal healthcare.
The Middle East & Africa animal vaccine market is expected to grow at a CAGR of 6.9% during the forecast period, showcasing the fastest-growing regional market. This growth is supported by expanding livestock production, greater focus on disease prevention, and improving access to veterinary healthcare across the region.
The UAE animal vaccine market could benefit from stronger disease-prevention efforts, as the UAE’s General Environmental Policy targets declaring the country free of priority animal diseases by 2030 and achieving 100% self-sufficiency in targeted animal products by 2040, supporting continued investment in livestock health and vaccination programs. The Africa animal vaccine market could benefit from expanding livestock production, as FAO projections indicate that Sub-Saharan Africa’s livestock production could grow at 3.3% annually through 2030, while cattle and buffalo numbers could reach 285 million and poultry numbers 1.46 billion, supporting greater requirements for preventive animal healthcare and vaccination.
The animal vaccine market is moderately fragmented, with competition involving established pharmaceutical companies, veterinary healthcare companies, biotechnology firms, specialized animal health manufacturers, and regional vaccine producers. The leading players in the Animal Vaccine Market include Zoetis Inc., Merck & Co., Inc. (Merck Animal Health), Boehringer Ingelheim Animal Health, Elanco Animal Health Inc., and Ceva Santé Animale, collectively accounting for approximately 25–28% of the market.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Tejas Zamde is a market research professional with over 2 years of experience in the technology, semiconductor, electronics, and automotive sectors. He specializes in market assessment, competitive intelligence, industry analysis, market sizing, demand analysis, and strategic research.
His experience includes analyzing technology trends, market dynamics, regulatory developments, supply-demand patterns, value chains, and competitive landscapes across global and regional markets. He has supported clients with opportunity assessment, customer segmentation, competitive benchmarking, and growth strategy development.
Bioelectric Medicine Market Size, Share, Growth, Analysis, 2034
PCB Design Software Market Size, Share, Growth, 2034
Printed Circuit Board Market Size, Share, Growth, 2034
Sensor Market Size, Share, Growth, Analysis, Report, 2034
Wireless Charging Market Size, Share, Growth, Analysis, Report, 2034
Cardiac Biomarkers Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com